Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Antibodies to the buried N terminus of rhinovirus VP4 exhibit cross-serotypic neutralization.

Katpally U, Fu TM, Freed DC, Casimiro DR, Smith TJ.

J Virol. 2009 Jul;83(14):7040-8. doi: 10.1128/JVI.00557-09. Epub 2009 Apr 29.

2.

The conserved N-terminus of human rhinovirus capsid protein VP4 contains membrane pore-forming activity and is a target for neutralizing antibodies.

Panjwani A, Asfor AS, Tuthill TJ.

J Gen Virol. 2016 Dec;97(12):3238-3242. doi: 10.1099/jgv.0.000629. Epub 2016 Oct 11.

3.

Identification and characterization of a cross-neutralization epitope of Enterovirus 71.

Liu CC, Chou AH, Lien SP, Lin HY, Liu SJ, Chang JY, Guo MS, Chow YH, Yang WS, Chang KH, Sia C, Chong P.

Vaccine. 2011 Jun 10;29(26):4362-72. doi: 10.1016/j.vaccine.2011.04.010. Epub 2011 Apr 16.

PMID:
21501643
4.

The refined structure of human rhinovirus 16 at 2.15 A resolution: implications for the viral life cycle.

Hadfield AT, Lee Wm, Zhao R, Oliveira MA, Minor I, Rueckert RR, Rossmann MG.

Structure. 1997 Mar 15;5(3):427-41.

5.

Species-specific and cross-reactive IgG1 antibody binding to viral capsid protein 1 (VP1) antigens of human rhinovirus species A, B and C.

Iwasaki J, Smith WA, Stone SR, Thomas WR, Hales BJ.

PLoS One. 2013 Aug 7;8(8):e70552. doi: 10.1371/journal.pone.0070552. eCollection 2013.

6.

Structure of human rhinovirus serotype 2 (HRV2).

Verdaguer N, Blaas D, Fita I.

J Mol Biol. 2000 Jul 28;300(5):1179-94.

PMID:
10903863
7.

Proposals for the classification of human rhinovirus species C into genotypically assigned types.

Simmonds P, McIntyre C, Savolainen-Kopra C, Tapparel C, Mackay IM, Hovi T.

J Gen Virol. 2010 Oct;91(Pt 10):2409-19. doi: 10.1099/vir.0.023994-0. Epub 2010 Jul 7. Review.

PMID:
20610666
8.

Crystal structure of a human rhinovirus neutralizing antibody complexed with a peptide derived from viral capsid protein VP2.

Tormo J, Blaas D, Parry NR, Rowlands D, Stuart D, Fita I.

EMBO J. 1994 May 15;13(10):2247-56.

9.

Human rhinovirus 3 at 3.0 A resolution.

Zhao R, Pevear DC, Kremer MJ, Giranda VL, Kofron JA, Kuhn RJ, Rossmann MG.

Structure. 1996 Oct 15;4(10):1205-20.

10.
11.
12.

Antibodies induced with recombinant VP1 from human rhinovirus exhibit cross-neutralisation.

Edlmayr J, Niespodziana K, Popow-Kraupp T, Krzyzanek V, Focke-Tejkl M, Blaas D, Grote M, Valenta R.

Eur Respir J. 2011 Jan;37(1):44-52. doi: 10.1183/09031936.00149109. Epub 2010 Jun 7.

13.

Ability of linear and cyclic peptides of neutralization antigenic site 1 of poliovirus type 1 to induce virus cross-reactive and neutralizing antibodies.

van der Werf S, Briand JP, Plaué S, Burckard J, Girard M, Van Regenmortel MH.

Res Virol. 1994 Nov-Dec;145(6):349-59.

PMID:
7535942
14.
15.

Rapid multiserotype detection of human rhinoviruses on optically coated silicon surfaces.

Ostroff R, Ettinger A, La H, Rihanek M, Zalman L, Meador J 3rd, Patick AK, Worland S, Polisky B.

J Clin Virol. 2001 May;21(2):105-17.

PMID:
11378491
16.

Comparison of rhinovirus antibody titers in children with asthma exacerbations and species-specific rhinovirus infection.

Iwasaki J, Smith WA, Khoo SK, Bizzintino J, Zhang G, Cox DW, Laing IA, Le Souëf PN, Thomas WR, Hales BJ.

J Allergy Clin Immunol. 2014 Jul;134(1):25-32. doi: 10.1016/j.jaci.2014.03.014. Epub 2014 Apr 24.

PMID:
24767874
17.

Identification of a new VP4 serotype of human rotaviruses.

Gerna G, Sears J, Hoshino Y, Steele AD, Nakagomi O, Sarasini A, Flores J.

Virology. 1994 Apr;200(1):66-71.

PMID:
8128639
18.

Different rhinovirus serotypes neutralized by antipeptide antibodies.

McCray J, Werner G.

Nature. 1987 Oct 22-28;329(6141):736-8.

PMID:
2444889
19.
20.

A part of the VP4 capsid protein exhibited by coxsackievirus B4 E2 is the target of antibodies contained in plasma from patients with type 1 diabetes.

Sauter P, Chehadeh W, Lobert PE, Lazrek M, Goffard A, Soumillon M, Caloone D, Vantyghem MC, Weill J, Fajardy I, Alm G, Lucas B, Hober D.

J Med Virol. 2008 May;80(5):866-78. doi: 10.1002/jmv.21171.

PMID:
18366069

Supplemental Content

Support Center